Neue Suche | Kongressdetail
Druckansicht
 
 

Triple Negative Breast Cancer Drug Development Summit

Evvnt Promotion / evvnt
-
28.04.2021 - 29.04.2021  Virtual
Time: 08:00 to 16:00
 
Kongressthemen
This is the primary industry platform specifically dedicated to providing you insight into the latest developments of safe and efficacious blockbuster therapies to treat triple negative breast cancer.

Breast cancer (BC) is the most common solid tumor in women, with the triple negative subtype associated with poorer overall survival and a higher probability of cancer recurrence.
Kongressorganizer (PCO)
Hanson Wade
Anmerkungen
Brochure: https://go.evvnt.com/729098-2?pid=4832

Speakers: Alison L. Hannah, Senior Vice President and Chief Medical Officer, CytomX Therapeutics, Angus Sinclair, VP Immuno-Oncology, IGM Biosciences, and more.
 

Anfragen und Anmeldung:

https://go.evvnt.com/729098-1?pid=4832
Herr Customer Services
 
Kategorien
Onkologie
Sprache
Englisch
Kongressgebühr
Conference Only (Drug Developer Pricing): USD 1999.00, Conference Only (Service Provider Pricing): USD 2499.00, Conference Only (Academic Pricing): USD 1799.00
Teilnehmer erwartet
1000 - 1000
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
 
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."

OÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation Hilfswerk AustriaEuropean Health Forum GasteinÖsterreichische Gesellschaft für Public HealthCenter of ExcellenceSwiss Tropical and Public Health InstituteÖsterreichisches Rotes KreuznewTree